A phase I trial to examine the safety, tolerability, and pharmacokinetics of ASN100 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2017
At a glance
- Drugs ASN 100 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 11 Oct 2017 Pharmacokinetic data from this trial were presented at IDWeek 2017, as per Arsanis Biosciences media release.
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 27 Oct 2016 Status changed from recruiting to completed, as per Arsanis Biosciences media release.